FDA nod triggers $30m milestone for Astute Medical

Astute Medical is in line to receive up to $30 million from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test.

Astute Medical said it's in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.

Astute Medical, CRG, Ortho-Clinical Diagnostics

News Well, 510(k), Diagnostics, Funding Roundup, Regulatory/Compliance, Renal

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1uRNVNn